WHO antimalarial trial guidelines: good science, bad news?

Area of Science:

• Malariology
• Pharmacology
• Genetics

Background:

• Accurate antimalarial drug efficacy estimation is crucial for malaria control.
• Distinguishing treatment failures from new infections in trials is challenging.
• Previous World Health Organization (WHO) guidelines risked underestimating drug failure rates.

Purpose of the Study:

• To discuss updated WHO guidelines for analyzing antimalarial drug efficacy.
• To explain the logic behind new genetic analyses for differentiating malaria infections.
• To prepare the malaria community for revised drug failure rate estimates.

Main Methods:

• Review of updated WHO guidelines on malaria case classification.
• Discussion of genetic profiling techniques for distinguishing infections.
• Analysis of implications for drug efficacy studies in varying transmission zones.

Main Results:

• Updated WHO guidelines offer more robust methods for analyzing malaria infections.
• New analyses improve the accuracy of differentiating treatment failures from new infections.
• Estimated antimalarial drug failure rates are expected to increase significantly in high transmission areas.

Conclusions:

• Revised WHO guidelines enhance the precision of antimalarial drug efficacy studies.
• Increased detection of treatment failures will likely lead to higher reported failure rates.
• The malaria research and control community must prepare for these updated estimates.